Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581709 | 0.75 | CYP1B1 (0.59) | ACHEALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL8220551 | 0.74 | TYR (0.67) | ALDH1A1MEN1PKMKMT2AMAPT | |
| SCHEMBL22843160 | 0.71 | L3MBTL1 (0.36) | ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL411536 | 0.71 | HTR2A (0.34) | — | |
| SCHEMBL21492162 | 0.69 | NR1H3 (0.49) | ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL30744324 | 0.69 | NR1H3 (0.49) | ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL23439163 | 0.68 | CYP1B1 (0.52) | ACHEALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL21598051 | 0.68 | CYP1A2 (0.54) | ACHEALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL383480 | 0.68 | CYP1B1 (0.52) | ACHEALDH1A1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL383479 | 0.68 | CYP1B1 (0.52) | ACHEALDH1A1KDM4ECYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2755952-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | ACHE 574/4885ALDH1A1 569/4885MEN1 1426/4885 |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | NNT, APOB, LDLR | ACHE 815/4885ALDH1A1 783/4885MEN1 2122/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | ACHE 574/4885ALDH1A1 569/4885MEN1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.